LIVE Q&A
We're looking at a potentially great setup for February as we work our way into the New Year. Omicron's wildfire-like spread since our last House Call (12/6) has been right on the heels of, and perhaps overlapping with, the Delta wave in some regions, and proved that even a mild[er] SARS-CoV-2 variant can be both highly disruptive and dangerous (for people and the system). We are in a Macro transition (Quad 1/4), which we'll discuss, the COVID-related data should improve from here, and there's been a flurry of pre-announcements and deals announced around JPM22 presentations. Concurrently, we're seeing the Acceleration of forward estimates hook up a bit in our screening data, and then there's the whole institutional flows and redemption cycle issue that Mike Taylor talked about with us on 1/7, and that should abate within a few weeks (CLICK HERE to watch the replay if you haven't found the time, yet). Put it all together and the Health Care sector is going to be exciting to cover and invest in this year - it's the 2022 version of the #reopening.
Submit your questions ahead of time via , and see below for what we've got queued up to start.
|
Hedgeye House Call + Q&A | The Doctor is In | Jan 18, 12:30 PM | The '22 Re-Opening, COVID, & Labor Please join us on Tuesday, January 18, at 12:30 PM ET Health Care Subscribers: CLICK HERE for event details (including video, materials links, and Q&A box), Add to Outlook |
THEME & TICKER UPDATES For Monday
Macro Quad Playbook & MicroQuad Utility | This Macro Quad 1 / "shallow" Macro Quad 1 or 4 regime change has been challenging. 2022 is off to a rocky and incredibly volatile start for many of our Position Monitor stocks. Thankfully, that includes our Short Ideas. We'll discuss what should work and how we're using the MicroQuads as a screening and risk management tool (we'll provide and review updated data/charts).
People Drive the U.S. Medical Economy | The staffing/labor crisis is no joke, and we fail to see how AMN and CCRN won't benefit over the foreseeable future. We're tracking everything and crunching all the data we can get our hands on (BLS, ADP, etc.). We'll discuss the latest trends in wages and areas of high demand and pressure. Are we at peak shortages?
LFST, ACHC, UHS | Mental / Behavioral Health remains a hot topic and area of seemingly never-ending investment and demand. We'll review how these stocks have performed and share updated thoughts on the theses, what management teams said, etc.
Position Monitor Review | We'll cover stocks including ONEM (remains a Long), DGX (our timely flip from Active Long -> Short Bench), and EXAS & TDOC (why they remain active Short Ideas).
As always, all data available upon request, and reach out to with any inquiries.
Thomas Tobin
Managing Director
Twitter
LinkedIn
